NARCO7T: Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy

Sponsor
Assistance Publique Hopitaux De Marseille (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05967832
Collaborator
(none)
30
1
2
18
1.7

Study Details

Study Description

Brief Summary

This study is part of the research on type 1 narcolepsy, a neurological pathology affecting mostly young subjects. The only biomarker currently available is the hypocretin assay, which shows a level below 110 pg/mL. However, the interpretation of this biomarker has limitations: the test is not widely available and it is rarely performed by practitioners. Even when performed, the interpretation of the level may not be consistent with the phenotype compatible with type 1 narcolepsy.

This study therefore aims to develop new tools to reduce the diagnostic delay. This would be the first study with 7T MRI that could achieve a level of spatial resolution sufficient to highlight volume changes in small brain structures such as the lateral hypothalamus whose narcolepsy-induced changes are not detected by lower resolution MRI.

Condition or Disease Intervention/Treatment Phase
  • Other: 7T MRI
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy: Pilot Study
Anticipated Study Start Date :
Oct 15, 2023
Anticipated Primary Completion Date :
Apr 14, 2025
Anticipated Study Completion Date :
Apr 14, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with type 1 narcolepsy

Patients with type 1 narcolepsy

Other: 7T MRI
Patients and healthy volunteers will have a 7T MRI

Active Comparator: Healthy volunteers

Other: 7T MRI
Patients and healthy volunteers will have a 7T MRI

Outcome Measures

Primary Outcome Measures

  1. Hypothalamic morphological difference [Month 0]

    Significant structural size difference between right and left lateral hypothalamus

Secondary Outcome Measures

  1. Microstructural abnormalities other than volume differences [Month 0]

    Significant difference in Diffusion and T2* values in the lateral hypothalamus

  2. Structural changes in hypothalamic nuclei other than the lateral hypothalamus [Month 0]

    Significant difference in volumes and T1 values in other regions of the posterior hypothalamus

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria for patients :
  1. Diagnosis of narcolepsy type 1 according to the diagnostic criteria of the International Classification of sleep disorders version 3 (ICSD-3, American Academy of Sleep Medicine, 2014) including a mean sleep latency of less than 8 minutes on the iterative sleep latency test associated with at least two direct REM sleep onset and the presence of cataplexy, and a cerebrospinal fluid hypocretin assay of less than 110 pg/ml performed by the reference radioimmunology (RIA) technique.

  2. Patient at least 18 years old

  3. Patient followed at the Narcolepsy and Rare Hypersomnias Competence Center, Timone Hospital, Marseille

  4. Patient having signed an informed consent

  5. Patient who is a beneficiary of or affiliated to a social security system

Exclusion Criteria for patient:
  1. Diagnosis of type 1 narcolepsy according to ICSD-3 criteria but without hypocretin assay

  2. Narcolepsy secondary to another neurological pathology or presence of a comorbid neurological pathology (multiple sclerosis, Steinert's myotonic dystrophy, head trauma, epilepsy)

  3. Protected patient: pregnant or breastfeeding woman, adult under guardianship or curatorship

  4. Contraindication to the realization of a 7T MRI: patient wearing a pacemaker, neurosurgical clips, artificial heart valve, surgical material or metal fragments in the body, dental or hearing prostheses, insulin pump, patient wearing an IUD, claustrophobic patient

  5. Patient unable to maintain decubitus position for the duration of the MRI (= 50 minutes)

Inclusion criteria for healthy volunteers:
  1. Subject 18 years of age or older

  2. Subject free of general illness, psychiatric disorders, and infectious, inflammatory, tumor, vascular, degenerative, or traumatic pathology of the central nervous system as determined during the medical interview.

  3. Subject who has signed an informed consent ;

  4. Subjects who are beneficiaries of or affiliated with a social security plan

Exclusion criteria for healthy volunteers:
  1. Protected subject: pregnant or breastfeeding woman, adult under guardianship or curatorship

  2. Subjects presenting a contraindication to the realization of a 7T MRI: patient with a pacemaker, neurosurgical clips, artificial heart valve, surgical material or metal fragments in the body, dental or auditory prostheses, insulin pump, patient with an IUD, claustrophobic patient

  3. Subject unable to maintain a decubitus position for the duration of the MRI (= 50 minutes)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Service Epileptologie et Rythmologie Cérébrale, Centre du Sommeil Marseille France 13005

Sponsors and Collaborators

  • Assistance Publique Hopitaux De Marseille

Investigators

  • Study Director: François Crémieux, AP-HM

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT05967832
Other Study ID Numbers:
  • RCAPHM22_0378
  • ID-RCB
First Posted:
Aug 1, 2023
Last Update Posted:
Aug 1, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique Hopitaux De Marseille
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2023